Sorry!! The article you are trying to read is not available now.
Thank you very much;
you're only a step away from
downloading your reports.

Onyx Pharmaceuticals Wins US Panel's Backing for Cancer Drug


In an 11-0 vote, government advisers said the benefits of a treatment for multiple myeloma outweighed the risks.

MINYANVILLE ORIGINAL Government advisers sent a strong recommendation in favor of Onyx Pharmaceuticals' (ONXX) cancer drug Kyprolis. In an 11-0 vote, the panel of advisers said the benefits of the drug outweighed the risks for patients with multiple myeloma.

The vote is a positive step toward Onyx winning US approval for the medicine. The Food and Drug Administration is expected to decide on market clearance for the drug by July 27. The company is seeking approval to sell Kyprolis as a treatment for patients who already received other therapies.

The positive panel vote Wednesday followed a report by the FDA's own staff earlier this week that raised serious safety concerns about Kyprolis, which also goes by the chemical name carfilzomib. One panelist abstained from voting.

(See Onyx Pharmaceuticals' Cancer Drug Faces Safety Questions)

Twitter: @brettchase

Follow the markets all day every day with a FREE 14 day trial to Buzz & Banter. Over 30 professional traders share their ideas in real-time. Learn more.
< Previous
  • 1
Next >
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.

Copyright 2011 Minyanville Media, Inc. All Rights Reserved.
Featured Videos